The Medical Technology Blog

Cardiovascular Device Business Product Launch

Everist Genomics is preparing for the market release in January 2012 for its CardioDefender diagnostic system, an FDA-approved and CE marked mobile phone ECG system that provides physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting. The system incorporates capabilities that enable physicians to diagnose and treat potentially life threatening arrhythmias that might otherwise be missed.

According to Everist, CardioDefender is the first system to deliver mobile, real-time, beat-by-beat, and quantitative heart monitoring and automated reporting by combining patented analytical mobile phone software with a Bluetooth device and electrodes. The electrodes, which are attached to the patient’s skin, transmit heart rhythm data to the Bluetooth device, which then transmits the data to the mobile phone. The software in the mobile phone analyses the heart rhythm data, and the data is sent to a cardiac monitoring centre which keeps an encrypted record of the data that can be reviewed by physicians. Physicians are also able to receive arrhythmia alerts via their mobile phone, tablet, laptop or desktop computer. In the event of a significant arrhythmia, the  system will automatically transmit an alert to the patient’s physician while the event is occurring.

Following regulatory clearances in 2010,  CardioDefender has already been deployed at more than 150 medical facilities in the US for postapproval commercial evaluation. Between January and October 2011, the number of patient days of heart rhythm monitoring performed with CardioDefender grew from fewer than 5,000 to more than 18,000 patient days per month.

For up to date information on product launches and much more, please click on the link to the Cardiovascular Device Business.




Espicom Business Intelligence

Tagged with:

Filed under: Medical Technology

Like this post? Subscribe to my RSS feed and get loads more!